Khalid Al-Rasadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Khalid Al-Rasadi has a total of 383 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Al-Zakwani
Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
12 shared publications Khalid Al-Waili
Department of Clinical Biochemistry, Sultan Qaboos University Hospital, University Medical City, Muscat, Oman
10 shared publications- Manfredi Rizzo
RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates
9 shared publications - Wael Almahmeed
Heart and Vascular Institute Cleveland Clinic Abu Dhabi UAE
8 shared publications - Raul Dias Santos
Hospital Israelita Albert Einstein, São Paulo
7 shared publications - Ali Talib Al Hinai
Sultan Qaboos University, College of Medicine & Health Sciences, Muscat, Oman
6 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 31
Elevated lipoprotein (a) and large apo(a) isoforms in Omani patients: a distinct cardiovascular risk profile
- 3 August 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 31
Open AccessElevated lipoprotein (a) and large apo(a) isoforms in Omani patients: a distinct cardiovascular risk profile
- Open Access
- 9 April 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 27, 101469
Editorial commentary: From prevalence to practice – implementing familial hypercholesterolemia screening in high-risk clinics using an implementation science framework
- 9 April 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 27, 101469
Open AccessEditorial commentary: From prevalence to practice – implementing familial hypercholesterolemia screening in high-risk clinics using an implementation science framework
- 11 March 2026
- Published by SAGE Publications in Angiology
Residual Cardiovascular Risk Associated with Non-HDL-C in Statin-Treated Patients: Data from the Gulf Triglyceride and Residual Cardiovascular Risk (Gulf CALLS) Cohort
Growing evidence suggests that lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels is associated with a reduced risk of cardiovascular diseases (CVD) events. However, data on this relationship remain scarce in the Arabian Gulf region. The Gulf TriglyCeride And ResiduaL CardiovascuLar RiSk (Gulf CALLS) study investigated the association between failure to achieve non-HDL-C targets (P = .028). In the present study involving very high-risk patients on statin therapy, failure to achieve non-HDL-C targets was associated with a significantly higher residual CVD risk, despite well-controlled LDL-C levels.
- 11 March 2026
- Published by SAGE Publications in Angiology
Residual Cardiovascular Risk Associated with Non-HDL-C in Statin-Treated Patients: Data from the Gulf Triglyceride and Residual Cardiovascular Risk (Gulf CALLS) Cohort
Growing evidence suggests that lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels is associated with a reduced risk of cardiovascular diseases (CVD) events. However, data on this relationship remain scarce in the Arabian Gulf region. The Gulf TriglyCeride And ResiduaL CardiovascuLar RiSk (Gulf CALLS) study investigated the association between failure to achieve non-HDL-C targets (P = .028). In the present study involving very high-risk patients on statin therapy, failure to achieve non-HDL-C targets was associated with a significantly higher residual CVD risk, despite well-controlled LDL-C levels.
- 26 May 2025
- Published by Springer Nature in Obesity Surgery
- p. 1-8
Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis
Background A significant number of patients encounter weight gain (WG) or inadequate weight loss (IWL) following bariatric surgery for obesity. Recent studies have explored the role of semaglutide in addressing weight management challenges in patients who have inadequate weight loss or weight gain after bariatric surgery. Despite such studies, a systematic review and meta-analysis evaluating the efficacy, safety and tolerability of semaglutide in this specific clinical context remains absent. Therefore, this study was undertaken to address this knowledge gap. Methods Databases were searched for randomized controlled trials (RCTs), case–control, cohort and observational studies involving use of semaglutide in the intervention arm post-bariatric surgery. Outcome was weight loss post-bariatric surgery. Results A total of six studies (300 participants) demonstrated significant weight reduction following semaglutide administration after bariatric surgery (WMD: − 15.730, 95% CI: − 22.140, − 9.320, p < 0.001). This effect remained robust in sensitivity analysis. Conclusion The current data encourages the use of semaglutide for managing WG or IWL post-bariatric surgery.
- 26 May 2025
- Published by Springer Nature in Obesity Surgery
- p. 1-8
Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis
Background A significant number of patients encounter weight gain (WG) or inadequate weight loss (IWL) following bariatric surgery for obesity. Recent studies have explored the role of semaglutide in addressing weight management challenges in patients who have inadequate weight loss or weight gain after bariatric surgery. Despite such studies, a systematic review and meta-analysis evaluating the efficacy, safety and tolerability of semaglutide in this specific clinical context remains absent. Therefore, this study was undertaken to address this knowledge gap. Methods Databases were searched for randomized controlled trials (RCTs), case–control, cohort and observational studies involving use of semaglutide in the intervention arm post-bariatric surgery. Outcome was weight loss post-bariatric surgery. Results A total of six studies (300 participants) demonstrated significant weight reduction following semaglutide administration after bariatric surgery (WMD: − 15.730, 95% CI: − 22.140, − 9.320, p < 0.001). This effect remained robust in sensitivity analysis. Conclusion The current data encourages the use of semaglutide for managing WG or IWL post-bariatric surgery.
- Open Access
- 3 June 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (3) , 997-1001
Efficacy of statin therapy in reducing epicardial adipose tissue: a systematic review and meta-analysis
Introduction: Understanding the effect of statins on epicardial adipose tissue (EAT) is important as it may help reduce the negative impact of EAT-derived molecules on the cardiovascular system and consequently on coronary artery disease. Thus, we aimed to perform a systematic review and meta-analysis to assess the impact of statin therapy on EAT.Methods: The study utilized Scopus, PubMed, Embase, and Web of Science to gather relevant studies on the impacts of statins on EAT until September 5th, 2023. The data collected underwent meta-analysis using Comprehensive Meta-Analysis (CMA) V4 software.Results: In the meta-analysis, three studies involving 512 subjects were ultimately incorporated. The findings indicated a significant decrease in EAT after treatment with statins (standardized mean difference (SMD = –0.507, 95% CI: –2.536, 1.521, p = 0.021).Conclusions: Statins appear to exert an additional cardiovascular therapeutic effect by reducing EAT.
- 3 June 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (3) , 997-1001
Open AccessEfficacy of statin therapy in reducing epicardial adipose tissue: a systematic review and meta-analysis
Introduction: Understanding the effect of statins on epicardial adipose tissue (EAT) is important as it may help reduce the negative impact of EAT-derived molecules on the cardiovascular system and consequently on coronary artery disease. Thus, we aimed to perform a systematic review and meta-analysis to assess the impact of statin therapy on EAT.Methods: The study utilized Scopus, PubMed, Embase, and Web of Science to gather relevant studies on the impacts of statins on EAT until September 5th, 2023. The data collected underwent meta-analysis using Comprehensive Meta-Analysis (CMA) V4 software.Results: In the meta-analysis, three studies involving 512 subjects were ultimately incorporated. The findings indicated a significant decrease in EAT after treatment with statins (standardized mean difference (SMD = –0.507, 95% CI: –2.536, 1.521, p = 0.021).Conclusions: Statins appear to exert an additional cardiovascular therapeutic effect by reducing EAT.
- Top Cited PapersOpen Access
- 2 May 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (25) , 2277-2291
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Thus, a low-density lipoprotein cholesterol (LDL-C) >10 mmol/L (>400 mg/dL) is suggestive of HoFH and warrants further evaluation. The statement also provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for family planning and pregnancy. Therapeutic decisions are based on the LDL-C level. Combination LDL-C-lowering therapy—both pharmacologic intervention and lipoprotein apheresis (LA)—is foundational. Addition of novel, efficacious therapies (i.e. inhibitors of proprotein convertase subtilisin/kexin type 9, followed by evinacumab and/or lomitapide) offers potential to attain LDL-C goal or reduce the need for LA. To improve HoFH care around the world, the statement recommends the creation of national screening programmes, education to improve awareness, and management guidelines that account for the local realities of care, including access to specialist centres, treatments, and cost. This updated statement provides guidance that is crucial to early diagnosis, better care, and improved cardiovascular health for patients with HoFH worldwide.
- 2 May 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (25) , 2277-2291
Top Cited PapersOpen Access2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Thus, a low-density lipoprotein cholesterol (LDL-C) >10 mmol/L (>400 mg/dL) is suggestive of HoFH and warrants further evaluation. The statement also provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for family planning and pregnancy. Therapeutic decisions are based on the LDL-C level. Combination LDL-C-lowering therapy—both pharmacologic intervention and lipoprotein apheresis (LA)—is foundational. Addition of novel, efficacious therapies (i.e. inhibitors of proprotein convertase subtilisin/kexin type 9, followed by evinacumab and/or lomitapide) offers potential to attain LDL-C goal or reduce the need for LA. To improve HoFH care around the world, the statement recommends the creation of national screening programmes, education to improve awareness, and management guidelines that account for the local realities of care, including access to specialist centres, treatments, and cost. This updated statement provides guidance that is crucial to early diagnosis, better care, and improved cardiovascular health for patients with HoFH worldwide.
- Open Access
- 3 January 2023
- Published by MDPI AG in Metabolites
- Vol. 13 (1) , 77
The Role of Advanced Glycation End Products on Dyslipidemia
Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.
- 3 January 2023
- Published by MDPI AG in Metabolites
- Vol. 13 (1) , 77
Open AccessThe Role of Advanced Glycation End Products on Dyslipidemia
Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.
- Open Access
- 26 December 2022
- Published by MDPI AG in Metabolites
- Vol. 13 (1) , 40
Associations between Periodontitis, COVID-19, and Cardiometabolic Complications: Molecular Mechanisms and Clinical Evidence
Periodontitis is a microbially driven, host-mediated disease that leads to loss of periodontal attachment and resorption of bone. It is associated with the elevation of systemic inflammatory markers and with the presence of systemic comorbidities. Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the majority of patients have mild symptoms, others experience important complications that can lead to death. After the spread of the COVID-19 pandemic, several investigations demonstrating the possible relationship between periodontitis and COVID-19 have been reported. In addition, both periodontal disease and COVID-19 seem to provoke and/or impair several cardiometabolic complications such as cardiovascular disease, type 2 diabetes, metabolic syndrome, dyslipidemia, insulin resistance, obesity, non-alcoholic fatty liver disease, and neurological and neuropsychiatric complications. Therefore, due to the increasing number of investigations focusing on the periodontitis-COVID-19 relationship and considering the severe complications that such an association might cause, this review aims to summarize all existing emerging evidence regarding the link between the periodontitis-COVID-19 axis and consequent cardiometabolic impairments.
- 26 December 2022
- Published by MDPI AG in Metabolites
- Vol. 13 (1) , 40
Open AccessAssociations between Periodontitis, COVID-19, and Cardiometabolic Complications: Molecular Mechanisms and Clinical Evidence
Periodontitis is a microbially driven, host-mediated disease that leads to loss of periodontal attachment and resorption of bone. It is associated with the elevation of systemic inflammatory markers and with the presence of systemic comorbidities. Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the majority of patients have mild symptoms, others experience important complications that can lead to death. After the spread of the COVID-19 pandemic, several investigations demonstrating the possible relationship between periodontitis and COVID-19 have been reported. In addition, both periodontal disease and COVID-19 seem to provoke and/or impair several cardiometabolic complications such as cardiovascular disease, type 2 diabetes, metabolic syndrome, dyslipidemia, insulin resistance, obesity, non-alcoholic fatty liver disease, and neurological and neuropsychiatric complications. Therefore, due to the increasing number of investigations focusing on the periodontitis-COVID-19 relationship and considering the severe complications that such an association might cause, this review aims to summarize all existing emerging evidence regarding the link between the periodontitis-COVID-19 axis and consequent cardiometabolic impairments.
- Top Cited Papers
- 1 November 2022
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 32 (8) , 525-533
Implications for the role of lipopolysaccharide in the development of atherosclerosis
- 1 November 2022
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 32 (8) , 525-533
Top Cited PapersImplications for the role of lipopolysaccharide in the development of atherosclerosis
- Open Access
- 13 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (20) , 6056
Effect of Bariatric Surgery on Intima Media Thickness: A Systematic Review and Meta-Analysis
Background: Obesity, and in particular extreme obesity, as a global health problem is an important risk factor for many diseases, including atherosclerotic cardiovascular disease (ACVD). Bariatric surgery might stop or slow atherogenesis by decreasing excessive weight in the early stages of atherogenesis, by suppressing low-grade systemic inflammation as well as by inhibiting oxidative stress and endothelial dysfunction. The aim of this meta-analysis was to provide an answer to whether bariatric surgery has a significant effect on intima-media thickness (IMT) which is a surrogate marker of early atherosclerosis and has a good correlation with atherosclerotic coronary heart disease. Methods: A systematic literature search in PubMed, Scopus, Embase, and Web of Science as well as grey literature was performed from inception to 1 July 2022. The meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V3 software. Overall, the estimate of effect size was measured by a random effects meta-analysis. To account for the heterogeneity of studies regarding study design, characteristics of the populations, and treatment duration, a random-effects model (using the DerSimonian–Laird method) and the generic inverse variance weighting approach were used. To assess the existence of publication bias in the meta-analysis, the funnel plot, Begg’s rank correlation, and Egger’s weighted regression tests were used. Results: The meta-analysis of 30 trials, including 1488 subjects, demonstrated a significant decrease in IMT after bariatric surgery. The reduction in IMT was also robust in the leave-one-out sensitivity analysis. It must be stressed that the results of the random-effects meta-regression did not suggest any relationship between the changes in IMT and delta body mass index (BMI) or duration of follow-up after the bariatric surgery. However, the subgroup analyses showed a better IMT reduction after laparoscopic sleeve gastrectomy (LSG) when compared to Roux-en-Y gastric bypass (RYGB). Within a year, the IMT follow-up values showed a further improvement. Conclusions: Bariatric surgery significantly reduced IMT. Significant associations were found between the surgery type and IMT changes, as well as a significant effect of follow-up duration on the changes of IMT after bariatric surgery.
- 13 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (20) , 6056
Open AccessEffect of Bariatric Surgery on Intima Media Thickness: A Systematic Review and Meta-Analysis
Background: Obesity, and in particular extreme obesity, as a global health problem is an important risk factor for many diseases, including atherosclerotic cardiovascular disease (ACVD). Bariatric surgery might stop or slow atherogenesis by decreasing excessive weight in the early stages of atherogenesis, by suppressing low-grade systemic inflammation as well as by inhibiting oxidative stress and endothelial dysfunction. The aim of this meta-analysis was to provide an answer to whether bariatric surgery has a significant effect on intima-media thickness (IMT) which is a surrogate marker of early atherosclerosis and has a good correlation with atherosclerotic coronary heart disease. Methods: A systematic literature search in PubMed, Scopus, Embase, and Web of Science as well as grey literature was performed from inception to 1 July 2022. The meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V3 software. Overall, the estimate of effect size was measured by a random effects meta-analysis. To account for the heterogeneity of studies regarding study design, characteristics of the populations, and treatment duration, a random-effects model (using the DerSimonian–Laird method) and the generic inverse variance weighting approach were used. To assess the existence of publication bias in the meta-analysis, the funnel plot, Begg’s rank correlation, and Egger’s weighted regression tests were used. Results: The meta-analysis of 30 trials, including 1488 subjects, demonstrated a significant decrease in IMT after bariatric surgery. The reduction in IMT was also robust in the leave-one-out sensitivity analysis. It must be stressed that the results of the random-effects meta-regression did not suggest any relationship between the changes in IMT and delta body mass index (BMI) or duration of follow-up after the bariatric surgery. However, the subgroup analyses showed a better IMT reduction after laparoscopic sleeve gastrectomy (LSG) when compared to Roux-en-Y gastric bypass (RYGB). Within a year, the IMT follow-up values showed a further improvement. Conclusions: Bariatric surgery significantly reduced IMT. Significant associations were found between the surgery type and IMT changes, as well as a significant effect of follow-up duration on the changes of IMT after bariatric surgery.